MedTrace Logo

Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study

NCT06972056 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1335

Last updated 2026-05-22

No results posted yet for this study

Summary

This goal of this study is to compare three medications used for migraine preventive treatment.

This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others.

Research participants will:

* Be randomly assigned to one of the three medications.
* Provide information about their migraine pattern using a daily headache diary and during research visits.

Conditions

Interventions

DRUG

Atogepant 60 mg

Atogepant at a dose up to 60 mg daily.

DRUG

Propranolol 160 mg

Daily propranolol up to 80 mg twice daily.

DRUG

Topiramate 100 mg

Daily topiramate, up to 50 mg twice daily

Sponsors & Collaborators

  • University of Iowa

    collaborator OTHER

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • AbbVie

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Todd J Schwedt, M.D. · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-09
Primary Completion
2029-03-01
Completion
2029-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06972056 on ClinicalTrials.gov